In models of pulmonary fibrosis induced by bleomycin (BLM) and silica, the administration of anti-IL-17A antibodies has been shown to reduce pulmonary fibrosis and extracellular matrix (ECM) deposition (24–26). Here, IL17A is linked to pulmonary fibrosis.